Skip to main content
SpringerLink
Log in

Medical Management of Metastatic Renal Cell Carcinoma

  • Chapter
  • First Online:
Urological Oncology

  • 1612 Accesses

Abstract

Metastatic renal cell carcinoma (RCC) has undergone a therapeutic revolution over the last decade. Initially treated with cytokine immunotherapy with dramatic effect in some but limited to no effect at most, therapy targeted at angiogenesis has become the mainstay. Tyrosine kinase inhibitors of the vascular endothelial growth factor (VEGF) receptor have emerged as standard initial therapy in metastatic RCC, with response rates approximately 30 % and duration of disease control 10–12 months. Resistance invariably develops, and sequential therapy with these agents has become the de facto standard. Other therapeutics targeting mammalian target of rapamycin (mTOR) have also shown some clinical efficacy. Major clinical data with the approved agents in metastatic RCC are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood. 1993;81(6):1414–23.

    CAS  PubMed  Google Scholar 

  2. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161(4):1947–53.

    CAS  PubMed  Google Scholar 

  3. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res. 1999;19(8):817–28.

    Article  CAS  PubMed  Google Scholar 

  4. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res. 1990;50(14):4190–4.

    CAS  PubMed  Google Scholar 

  5. Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep. 2002;4(6):510–4.

    Article  PubMed  Google Scholar 

  6. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  7. Yang JC, Sherry RM, Steinberg SM, Topalian SL, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

    CAS  PubMed  Google Scholar 

  9. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996;14(8):2410–1.

    CAS  PubMed  Google Scholar 

  10. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):148–54.

    CAS  PubMed  Google Scholar 

  11. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17(9):2859–67.

    CAS  PubMed  Google Scholar 

  12. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999;353(9146):14–7.

    Google Scholar 

  13. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin Jr WG. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995;269(5229):1444–6.

    Article  CAS  PubMed  Google Scholar 

  14. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.

    Article  CAS  PubMed  Google Scholar 

  15. Cockman ME, Masson N, Mole DR, Jaakkola P, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275(33):25733–41.

    Article  CAS  PubMed  Google Scholar 

  16. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.

    Article  CAS  PubMed  Google Scholar 

  17. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(8):1280–9.

    Article  CAS  PubMed  Google Scholar 

  18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–8.

    Article  CAS  PubMed  Google Scholar 

  19. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25(29):4536–41.

    Article  CAS  PubMed  Google Scholar 

  20. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–50.

    Article  CAS  PubMed  Google Scholar 

  21. Rini BI, Halabi S, Rosenberg JE, Stadler WM, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Melichar B, Koralewski P, Ravaud A, Pluzanska A, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008;19(8):1470–6.

    Article  CAS  PubMed  Google Scholar 

  23. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46(7):1116–9.

    Article  CAS  PubMed  Google Scholar 

  24. Mendel DB, Laird AD, Xin X, Louie SG, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–37.

    CAS  PubMed  Google Scholar 

  25. Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Bard RH, Mydlo JH, Freed SZ. Detection of tumor angiogenesis factor in adenocarcinoma of kidney. Urology. 1986;27(5):447–50.

    Article  CAS  PubMed  Google Scholar 

  27. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.

    Article  CAS  PubMed  Google Scholar 

  28. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009;27(19):3225–34.

    Article  CAS  PubMed  Google Scholar 

  29. Presta LG, Chen H, O’Connor SJ, Chisholm V, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–9.

    CAS  PubMed  Google Scholar 

  30. Yang JC, Haworth L, Sherry RM, Hwu P, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004;10(18 Pt 2):6367S–70.

    Article  CAS  PubMed  Google Scholar 

  32. Rini BI, Halabi S, Rosenberg JE, Stadler WM, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Escudier B, Pluzanska A, Koralewski P, Ravaud A, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.

    Article  PubMed  Google Scholar 

  34. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  35. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Escudier B, Eisen T, Stadler WM, Szczylik C, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  37. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975–84.

    Article  PubMed  Google Scholar 

  38. Rini BI, Wilding G, Hudes G, Stadler WM, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(27):4462–8.

    Article  CAS  PubMed  Google Scholar 

  39. Rini BI, Escudier B, Tomczak P, Kaprin A, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.

    Article  CAS  PubMed  Google Scholar 

  40. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  41. Motzer RJ, Escudier B, Oudard S, Hutson TE, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–65.

    Article  CAS  PubMed  Google Scholar 

  42. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96.

    Article  CAS  PubMed  Google Scholar 

  43. Rini BI, Garcia JA, Cooney MM, Elson P, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009;15(19):6277–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Rini BI, Stein M, Shannon P, Eddy S, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117(4):758–67.

    Article  CAS  PubMed  Google Scholar 

  45. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):24–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15(7):2497–506.

    Article  CAS  PubMed  Google Scholar 

  47. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer. 2001;8(3):219–25.

    Article  CAS  PubMed  Google Scholar 

  48. Wilhelm SM, Carter C, Tang L, Wilkie D, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.

    Article  CAS  PubMed  Google Scholar 

  49. Garcia JA, Hutson TE, Elson P, Cowey CL, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116(23):5383–90.

    Article  CAS  PubMed  Google Scholar 

  50. Sternberg CN, Davis ID, Mardiak J, Szczylik C, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    Article  CAS  PubMed  Google Scholar 

  51. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.

    Article  CAS  PubMed  Google Scholar 

  52. Wullschleger S, Loewith R, Oppliger W, Hall MN. Molecular organization of target of rapamycin complex 2. J Biol Chem. 2005;280(35):30697–704.

    Article  CAS  PubMed  Google Scholar 

  53. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4(4):257–62.

    Article  CAS  PubMed  Google Scholar 

  54. Cho D, Signoretti S, Dabora S, Regan M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5(6):379–85.

    Article  CAS  PubMed  Google Scholar 

  55. Maroto JP, Hudes G, Dutcher JP, Logan TF, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol. 2011;29(13):1750–6.

    Article  CAS  PubMed  Google Scholar 

  56. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832–41.

    Article  PubMed  Google Scholar 

  57. Atkins MB, Hidalgo M, Stadler WM, Logan TF, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–18.

    Article  CAS  PubMed  Google Scholar 

  58. Dutcher JP, de Souza P, McDermott D, Figlin RA, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–9.

    Article  CAS  PubMed  Google Scholar 

  59. Motzer RJ, Escudier B, Oudard S, Hutson TE, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Solid Tumor Oncology, Cleveland Clinic Foundation Taussig Cancer Center, Cleveland, OH, USA

    Brian I. Rini MD & Ronald M. Bukowski MD

Authors
  1. Brian I. Rini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald M. Bukowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian I. Rini MD .

Editor information

Editors and Affiliations

  1. Department of Urology, Homerton University Hospital & Formerly St. Bartholomew's Hospital, London, United Kingdom

    Vinod H. Nargund

  2. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Derek Raghavan

  3. Radiation Oncology, Cedars Sinai Cancer Center, Los Angeles, California, USA

    Howard M. Sandler

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Rini, B.I., Bukowski, R.M. (2015). Medical Management of Metastatic Renal Cell Carcinoma. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-482-1_24

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-481-4

  • Online ISBN: 978-0-85729-482-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation